The Barostim System is FDA-approved and indicated for patients who are NYHA Class III or Class II (who had a recent history of Class III) despite treatment with guideline-directed medical therapies (medications and devices), have a left ventricular ejection fraction of ≤ 35%, and a NT-proBNP <1600 pg/mL. Barostim delivers Baroreflex Activation Therapy for improvement of patients’ heart failure functional status, six-minute hall walk, and quality of life.
BENEFIT-HF is a clinical trial evaluating Barostim in an expanded heart failure population. While this trial includes patients within the currently approved indication, it also includes an expanded population for whom the safety and effectiveness of the device have not yet been established. Barostim is not FDA-approved for use in this expanded patient population.
CAUTION: Investigational use of device. Federal law restricts this device to sale by or on the order of a physician. See Instructions for Use (900133-001) for complete instructions for use and a description of indications, contraindications, warnings, precautions and adverse events.